drugset / Trial / NCT07493980
Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of JSKN016 combined with toripalimab and carboplatin as a neoadjuvant treatment regimen in patients with resectable stage II-III NSCLC.
Timeline
- Start
- 2026-03
- Primary completion
- 2027-01
- Completion
- 2029-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | JSKN016 | Unknown | 4 mg/kg | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |